GlassScriptPhysician profile
Baldomero Deleon
NPI 1891819090
$4,114.14
in general payments reported to CMS, 2019-2025
15 companies · $560 in 2025
The $560 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $786 · 2021: $1,100 · 2022: $375 · 2023: $553 · 2024: $383 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459 · Education: $36.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.81 |
| Education | $36.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $949.95 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $816.01 | 2019-2025 | Ofev, Jardiance |
| Amarin Pharma, INC. | $675.54 | 2020-2021 | |
| Glaxosmithkline, LLC. | $325.04 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $289.10 | 2024-2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $247.63 | 2021-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $194.13 | 2020-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $176.94 | 2022-2023 | Veozah |
| Arbor Pharmaceuticals, INC. | $153.90 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $83.59 | 2020 | |
| Exact Sciences Corporation | $70.46 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $52.40 | 2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $35.03 | 2019-2020 | |
| Genentech USA, INC. | $24.35 | 2019 | |
| Neurocrine Biosciences, INC. | $20.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baldomero Deleon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.